Effects of the Variants of Activin Receptor-like Kinase-1 and 2 on the Lipid Profile of Patients with Coronary Heart Disease

Introduction:Coronary heart disease (CHD) due to atherosclerosis is a multifactorial disease with high morbidity caused by interaction of various genetic and environmental factors. Hyperlipidemia which is accepted as the most important risk factor for atherosclerosis; characterized by high concentra...

Full description

Bibliographic Details
Main Authors:	Ayşegül Başak Akadam Teker, Erhan Teker, Hülya Yılmaz Aydoğan
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2020-09-01
Series:	İstanbul Medical Journal
Subjects:	mutation coronary hearth disease alk1 alk2
Online Access:	http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/effects-of-the-variants-of-activin-receptor-like-k/40214

Similar Items

Crizotinib: A comprehensive review
by: Arvind Sahu, et al.
Published: (2013-01-01)

Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase
by: Cheng-Han Jiang, et al.
Published: (2018-07-01)

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
by: Hao Huang
Published: (2018-11-01)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
by: Zeng L, et al.
Published: (2020-07-01)

The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
by: Stephen P. Ducray, et al.
Published: (2019-07-01)

Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non‐small cell lung cancer
by: Donghui Hou, et al.
Published: (2021-09-01)

Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
by: Peng SONG, et al.
Published: (2018-09-01)

Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase‐positive lung cancer
by: Kengo Tanigawa, et al.
Published: (2019-10-01)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
by: Serena Stadler, et al.
Published: (2018-04-01)

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology
by: Adriane F. Evangelista, et al.
Published: (2017-05-01)

An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report
by: Masahide Takeda, et al.
Published: (2019-04-01)

Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report
by: Cai C, et al.
Published: (2020-08-01)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
by: Xiaoling Song, et al.
Published: (2021-09-01)

Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn’s DiseaseSummary
by: Takahiko Toyonaga, et al.
Published: (2020-01-01)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
by: Xueqian Wu, et al.
Published: (2020-06-01)

ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models
by: Letizia Astrologo, et al.
Published: (2017-12-01)

Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors
by: Oddrun Elise Olsen, et al.
Published: (2020-03-01)

Der ALK-Rezeptor in zellulären Modellen des humanen Neuroblastomkrebses: Aktivierung und Signalisierung
by: Aksak, Laura Jacqueline
Published: (2018)

EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
by: Stefan Diem, et al.
Published: (2013-06-01)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
by: Zilan Song, et al.
Published: (2015-01-01)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Amino acid residues critical for anaplastic lymphoma kinase receptor cleavage
by: Shetty, Kunal
Published: (2016)

TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity
by: Arjan van Caam, et al.
Published: (2017-05-01)

Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2014-12-01)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
by: Suzanne D. Turner
Published: (2017-10-01)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
by: Chunlai Feng, et al.
Published: (2021-08-01)

Nodal promotes glioblastoma cell growth
by: Tanya ede Silva, et al.
Published: (2012-04-01)

Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
by: Huamiao Zhou, et al.
Published: (2021-06-01)

How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report
by: Antonello Sica, et al.
Published: (2021-01-01)

The role of ALK1 and ALK5 receptors, and their cognate Smads, in TGFβ1-mediated podosome-formation in aortic endothelial cells
by: Dos Santos Curado, Filipa
Published: (2013)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
by: Shih‐Hao Huang, et al.
Published: (2019-12-01)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
by: Peng Song, et al.
Published: (2020-05-01)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
by: Xibin Zhuang, et al.
Published: (2019-06-01)

L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
by: Jian Li, et al.
Published: (2017-02-01)

Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report
by: Qingzhi Song, et al.
Published: (2021-04-01)

Koroner Kalp Hastalarında PCSK9 E670G ve N425S Gen Varyasyonlarının Etkisinin Türk Toplumunda Değerlendirilmesi
by: Hülya Yılmaz Aydoğan, et al.
Published: (2018-04-01)

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
by: Jikui Guan, et al.
Published: (2017-10-01)

Emerging Roles of ALK in Immunity and Insights for Immunotherapy
by: Lan Wang, et al.
Published: (2020-02-01)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01)

A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors  and Chemotherapy
by: Jue WANG, et al.
Published: (2021-05-01)